Emergency by Referral, Mon-Fri 8:00am-Midnight

Back to Blog

The Future of Veterinary Medicine – Here Today!

Aug 28, 2015

Dear Friends and Colleagues,

I hope this letter finds all of you well. I am excited to introduce our new company, Innogenics. We are a diagnostic company offering genomic based testing for companion animals. I am the Chief Medical Officer and the rest of our executive team brings the needed experience in veterinary pathology, comparative oncology, business development and marketing needed to make Innogenics successful. Our first product, available now, is our Enlight Assay ®. This test will give you the gene expression patterns of 30 canine genes that are important to all veterinarians who diagnose and treat cancer.

This information will allow you to give your clients more accurate information about diagnosis, prognosis and therapy. Gene expression and mutation analysis has become exceedingly important in human medicine, particularly in the field of oncology. Unfortunately genomic testing in companion animals has been impeded by a number of challenges. Innogenics has developed an automated, robust, reproducible, and cost-effective assay that uses small amounts of formalin-fixed paraffin embedded (FFPE) samples prepared on glass slides.

One of the key features of our technology is that your workflow remains unchanged. You can still submit your surgical biopsy samples to your laboratory of choice. If the diagnosis is cancer, you simply send Innogenics one H & E stained slide and 5 unstained slides.

Innogenics is proud to introduce an affordably priced molecular approach to companion animal diagnostics and therapeutics that has substantial advantages over current practices. We all know how expensive (and unreliable) multiple immunohistochemical (IHC) stains are and how much time is wasted waiting for results.  Because our technology works reliably on FFPE specimens and our results are rapid, Innogenics will save you time and your client’s money.

Innogenics is the company that will bring personalized cancer therapy to veterinarians by providing comprehensive, sensitive and accurate cancer genome analysis in 'real-time'.

If you would like any more information or to find out how to submit samples to us, please visit our web site www.innogenics.org.

Thank you,

Dr. Gerald S. Post

The Veterinary Cancer Center